Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chapel Hill, North Carolina 27599


This study is intended to provide statistically robust evidence that Symbios Demineralized Cortical-cancellous granule mix, Symbios OsteoGraf LD-300, and OsteoGraf/N-300 combined with Symbios OsteoShield Collagen Resorbable Membrane can adequately support the alveolus during ridge augmentation procedures, reducing the dimensional changes of both the alveolus and the overlying soft tissues. Additionally, a comparison between each material will be made, providing further evidence of each materials' ability to preserve the alveolus. It is intended to define in objective terms the response of the hard and soft tissues to ridge augmentation.


Inclusion Criteria: 1. Provision of informed consent 2. ≥ 18 years and ≤ 75 years 3. Good physical health (ASAI/II) 4. Extraction of maxillary premolar, canine or incisor, or mandibular premolar and canine required 5. Teeth adjacent (mesial and distal) to study site must consist of two stable natural teeth with minimal restorations, without signs of periodontal bone loss (> 3 mm) and/or significant soft tissue deficiencies Exclusion Criteria: 1. Buccal plate dehiscence and/or fenestration >3mm at study site following extraction 2. Untreated rampant caries and uncontrolled periodontal disease 3. Inadequate oral hygiene (estimated plaque score >20%) 4. Smokers using more than 10 cigarettes or equivalent per day 5. Smokeless tobacco use or e-cigarette use 6. Compromised physical health and/or uncontrolled or severe systemic diseases including: ASA III/IV Metabolic bone disease History of malignancy History or radiotherapy or chemotherapy for malignancy in the past 5 years History of autoimmune disease Long-term steroidal or antibiotic therapy Uncontrolled diabetes Known alcohol or drug abuse 7. Systemic or local disease or condition that would compromise post-operative healing 8. Use of any substance or medication that will influence bone metabolism 9. Known pregnancy 10. Unable or unwilling to return for follow-up visits for a period of 6 months 11. Unlikely to be able to comply with study procedures according to Investigators judgement 12. Involvement in the planning and conduct of the study 13. Previous enrollment or randomization of treatment in the present study



Primary Contact:

Principal Investigator
Jonathan Reside, DDS MS
Dept. of Periodontology

Backup Contact:


Location Contact:

Chapel Hill, North Carolina 27599
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.